Impact of Ligand Size and Conjugation Chemistry on the Performance of Universal Chimeric Antigen Receptor T-Cells for Tumor Killing.


Journal

Bioconjugate chemistry
ISSN: 1520-4812
Titre abrégé: Bioconjug Chem
Pays: United States
ID NLM: 9010319

Informations de publication

Date de publication:
15 07 2020
Historique:
pubmed: 10 6 2020
medline: 22 6 2021
entrez: 10 6 2020
Statut: ppublish

Résumé

All Universal Chimeric Antigen Receptor T-cells (UniCAR T-cells) are T-cells which have been engineered to recognize a haptenated ligand. Due to this feature, UniCAR T-cells have the potential to mediate a potent and selective tumor killing only in the presence of a haptenated tumor ligand, thus avoiding the long-lasting biocidal effects of conventional CAR T-cells. We have used fluorescein-labeled versions of small organic ligands and different antibody formats specific to carbonic anhydrase IX (a tumor-associated antigen) in order to assess whether the killing potential of UniCAR T-cells depended on the molecular features of the haptenated molecule. Both small molecule ligands and larger antibody fragments were potent in mediating tumor cell killing over a broad concentration range. Antibodies could be conveniently used both in IgG format and as smaller diabody fragments. Importantly, the use of site-specific chemical modification strategies for the antibody coupling to fluorescein led to a substantial improvement of tumor cell killing performance, compared to the random modification of primary amino groups on the antibody surface.

Identifiants

pubmed: 32515934
doi: 10.1021/acs.bioconjchem.0c00258
doi:

Substances chimiques

Antigens, Neoplasm 0
Ligands 0
Receptors, Chimeric Antigen 0
CA9 protein, human EC 4.2.1.1
Carbonic Anhydrase IX EC 4.2.1.1
Fluorescein TPY09G7XIR

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1775-1783

Auteurs

Christian Pellegrino (C)

Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology (ETH Zürich), 8093 Zurich, Switzerland.

Nicholas Favalli (N)

Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology (ETH Zürich), 8093 Zurich, Switzerland.

Michael Sandholzer (M)

Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology (ETH Zürich), 8093 Zurich, Switzerland.

Laura Volta (L)

Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology (ETH Zürich), 8093 Zurich, Switzerland.

Gabriele Bassi (G)

Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology (ETH Zürich), 8093 Zurich, Switzerland.

Jacopo Millul (J)

Philochem AG, Libernstrasse 3, 8112 Otelfingen, Switzerland.

Samuele Cazzamalli (S)

Philochem AG, Libernstrasse 3, 8112 Otelfingen, Switzerland.

Mattia Matasci (M)

Philochem AG, Libernstrasse 3, 8112 Otelfingen, Switzerland.

Alessandra Villa (A)

Philochem AG, Libernstrasse 3, 8112 Otelfingen, Switzerland.

Renier Myburgh (R)

Department of Medical Oncology and Hematology, Comprehensive Cancer Center Zurich (CCCZ), University Hospital Zurich and University of Zürich, 8091 Zürich, Switzerland.

Markus G Manz (MG)

Department of Medical Oncology and Hematology, Comprehensive Cancer Center Zurich (CCCZ), University Hospital Zurich and University of Zürich, 8091 Zürich, Switzerland.

Dario Neri (D)

Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology (ETH Zürich), 8093 Zurich, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH